Study Stopped
lack of recruitment
Improving SWAllowing After Stroke With Transcranial Direct Current Stimulation
iSWAT
Therapeutic Impact of tDCS on Dysphagia in the Acute Phase of Stroke / Impact thérapeutique de la tDCS Sur la Dysphagie en Phase Aigue de l'Accident Vasculaire cérébral
1 other identifier
interventional
100
1 country
1
Brief Summary
In the acute phase of stroke, dysphagia (difficulty/inability to swallow) is a common problem that can have serious consequences such as aspiration pneumonia, increased lenght of hospitalisation, and death. It would be interesting to enhance the therapeutic effect of swallowing retraining by means on non-invasive brain stimulation such as transcranial direct current stimulation (tDCS). Hypothesis: during the acute phase of stroke, applying tDCS over the brain during the revalidation and/or supervised feeding improves dysphagia significantly when compared to sham tDCS.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Jan 2013
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
December 27, 2012
CompletedFirst Posted
Study publicly available on registry
January 1, 2013
CompletedStudy Start
First participant enrolled
January 1, 2013
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 8, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
May 8, 2023
CompletedMay 10, 2023
May 1, 2023
10.4 years
December 27, 2012
May 8, 2023
Conditions
Outcome Measures
Primary Outcomes (2)
VideoFluoroscopy (VFSS)
The patients will be asked to swallow radiocontrast agent liquid during RX (radiography) video-recording. The speed of swallowing, whether there is aspiration or stasis will be quantified off-line on videotape
baseline, end of acute stroke phase, follow up (3, 6, 12 months)
Fiberoptic Endoscopic Evaluation of Swallowing (FEES)
A laryngoscope (attached to a camera and a color monitor) will be passed through the nostril. The patients will be asked to swallow small quantities of liquids and foods, and the quality of swallowing will be assessed off-line (videotaped examination). The base of the tongue, pharynx and larynx will be viewed.
baseline, end of acute stroke phase, follow up (3, 6, 12 months)
Secondary Outcomes (3)
NIH Stroke Scale
baseline, end of acute stroke phase, follow up (3, 6, 12 months)
clinical record
baseline, end of acute stroke phase, follow up (3, 6, 12 months)
quality-of-life (QOL) questionnaire designed for dysphagia (SWAL-QOL)
baseline, end of acute stroke phase, follow up (3, 6, 12 months)
Study Arms (2)
real tDCS
ACTIVE COMPARATORpatients will receive non-invasive and painless brain stimulation over the rain areas involved in swallowing. tDCS will be applied during swallowing therapy, during 20 minutes
sham tDCS
PLACEBO COMPARATORthis will be exactly as for "real tDCS" unless that the tDCS will be rapidly turned off, unbeknown from patients-therapist-examinator (double-blind trial)
Interventions
tDCS is a safe and painless transcranial stimulation that modulates brain activity and could improve stroke recovery. Electrodes in soaked sponges are placed over specific brain regions and held with an elastic band. Direct current is then applied through the electrodes. The patients may feel nothing or a slight tingling under the electrodes.
Eligibility Criteria
You may qualify if:
- \- acute stroke (ischemic / hemorrhagic) with dysphagia
You may not qualify if:
- major swallowing impairment before the stroke
- troubles of comprehension impairing communication
- major cognitive dysfunction, neuro-degenerative disease, or major psychiatric condition (e.g. depression, Alzheimer's disease, …)
- very unstable health issue (e.g. severe cardiac dyscfct, end-stage renal failure, unstable diabetes, …)
- intracranial metal and/or devices excluding tDCS application
- chronic intake of major drugs modifying brain activity (e.g. AEDs, antipsychotics)
- regular use of alcohol or recreative drugs
- epilepsy
- pregnancy
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
University Hospital of Mont-Godinne : CHU Mont-Godinne UCL
Yvoir, Namur, 5530, Belgium
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Yves Vandermeeren, MD, PhD
University Hospital of Mont-Godinne
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- QUADRUPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
- Masking Details
- randomisation by computer
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor (MD, PhD)
Study Record Dates
First Submitted
December 27, 2012
First Posted
January 1, 2013
Study Start
January 1, 2013
Primary Completion
May 8, 2023
Study Completion
May 8, 2023
Last Updated
May 10, 2023
Record last verified: 2023-05